Charles River Laboratories International, Inc.

NYSE:CRL Rapport sur les actions

Capitalisation boursière : US$10.0b

Charles River Laboratories International Gestion

Gestion contrôle des critères 4/4

Le PDG Charles River Laboratories International est Jim Foster, nommé en Jan1991, a un mandat de 33.83 ans. La rémunération annuelle totale est $ 14.10M, composée du salaire de 10.4% et des bonus 89.6%, y compris les actions et options de la société. détient directement 0.45% des actions de la société, d'une valeur de $ 45.39M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 5 ans et 7.3 ans.

Informations clés

Jim Foster

Directeur général

US$14.1m

Rémunération totale

Pourcentage du salaire du PDG10.4%
Durée du mandat du directeur général33.8yrs
Propriété du PDG0.5%
Durée moyenne d'occupation des postes de direction5yrs
Durée moyenne du mandat des membres du conseil d'administration7.3yrs

Mises à jour récentes de la gestion

Recent updates

Charles River Laboratories: Not The Right Time To Own At This Point In The Cycle

Nov 19

Charles River Laboratories International (NYSE:CRL) Has A Somewhat Strained Balance Sheet

Oct 26
Charles River Laboratories International (NYSE:CRL) Has A Somewhat Strained Balance Sheet

What Charles River Laboratories International, Inc.'s (NYSE:CRL) P/E Is Not Telling You

Oct 11
What Charles River Laboratories International, Inc.'s (NYSE:CRL) P/E Is Not Telling You

Why Charles River Laboratories International, Inc. (NYSE:CRL) Could Be Worth Watching

Sep 10
Why Charles River Laboratories International, Inc. (NYSE:CRL) Could Be Worth Watching

US$227: That's What Analysts Think Charles River Laboratories International, Inc. (NYSE:CRL) Is Worth After Its Latest Results

Aug 10
US$227: That's What Analysts Think Charles River Laboratories International, Inc. (NYSE:CRL) Is Worth After Its Latest Results

Charles River Laboratories: Q2, Cost Structure Streamlining (Rating Upgrade)

Aug 10

Charles River Laboratories International (NYSE:CRL) Takes On Some Risk With Its Use Of Debt

Jul 26
Charles River Laboratories International (NYSE:CRL) Takes On Some Risk With Its Use Of Debt

Risks To Shareholder Returns Are Elevated At These Prices For Charles River Laboratories International, Inc. (NYSE:CRL)

Jul 11
Risks To Shareholder Returns Are Elevated At These Prices For Charles River Laboratories International, Inc. (NYSE:CRL)

Charles River Laboratories: Fair Valuation Against Fundamentals

May 31

What Is Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Doing?

May 25
What Is Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Doing?

Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 30% Discount?

Apr 27
Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 30% Discount?

Charles River Laboratories International, Inc.'s (NYSE:CRL) Price Is Out Of Tune With Earnings

Apr 11
Charles River Laboratories International, Inc.'s (NYSE:CRL) Price Is Out Of Tune With Earnings

Charles River Laboratories International (NYSE:CRL) Has A Pretty Healthy Balance Sheet

Mar 27
Charles River Laboratories International (NYSE:CRL) Has A Pretty Healthy Balance Sheet

Charles River Laboratories International (NYSE:CRL) Strong Profits May Be Masking Some Underlying Issues

Feb 21
Charles River Laboratories International (NYSE:CRL) Strong Profits May Be Masking Some Underlying Issues

Charles River Laboratories: Weak Biopharma Spending Is Transitory; Initiate With 'Hold'

Feb 16

Is It Time To Consider Buying Charles River Laboratories International, Inc. (NYSE:CRL)?

Jan 17
Is It Time To Consider Buying Charles River Laboratories International, Inc. (NYSE:CRL)?

Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Not Quite Adding Up

Jan 02
Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Not Quite Adding Up

Charles River Laboratories International (NYSE:CRL) Ticks All The Boxes When It Comes To Earnings Growth

Dec 17
Charles River Laboratories International (NYSE:CRL) Ticks All The Boxes When It Comes To Earnings Growth

Charles River Laboratories: Mr. Market Went From Overvaluation To Undervaluation

Nov 26

Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 29% Discount?

Nov 12
Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 29% Discount?

Charles River: Q3 Points To Ongoing Deterioration

Nov 09

Charles River Laboratories International (NYSE:CRL) Has A Somewhat Strained Balance Sheet

Oct 27
Charles River Laboratories International (NYSE:CRL) Has A Somewhat Strained Balance Sheet

At US$197, Is Charles River Laboratories International, Inc. (NYSE:CRL) Worth Looking At Closely?

Oct 12
At US$197, Is Charles River Laboratories International, Inc. (NYSE:CRL) Worth Looking At Closely?

Charles River Laboratories: Diving Into The Lab (Rating Upgrade)

Oct 06

Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 27% Discount?

Aug 10
Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 27% Discount?

Charles River Laboratories: Very Attractive After The Pullback

Jul 26

Does Charles River Laboratories International (NYSE:CRL) Deserve A Spot On Your Watchlist?

Jul 22
Does Charles River Laboratories International (NYSE:CRL) Deserve A Spot On Your Watchlist?

Charles River Laboratories International (NYSE:CRL) Seems To Use Debt Quite Sensibly

Jul 03
Charles River Laboratories International (NYSE:CRL) Seems To Use Debt Quite Sensibly

When Should You Buy Charles River Laboratories International, Inc. (NYSE:CRL)?

Jun 19
When Should You Buy Charles River Laboratories International, Inc. (NYSE:CRL)?

Analyse de la rémunération des PDG

Comment la rémunération de Jim Foster a-t-elle évolué par rapport aux bénéfices de Charles River Laboratories International?
DateRémunération totaleSalaireBénéfices de l'entreprise
Sep 28 2024n/an/a

US$413m

Jun 29 2024n/an/a

US$432m

Mar 30 2024n/an/a

US$439m

Dec 30 2023n/an/a

US$475m

Sep 30 2023n/an/a

US$475m

Jul 01 2023n/an/a

US$484m

Apr 01 2023n/an/a

US$496m

Dec 31 2022US$13mUS$1m

US$486m

Sep 24 2022n/an/a

US$436m

Jun 25 2022n/an/a

US$443m

Mar 26 2022n/an/a

US$422m

Dec 25 2021US$14mUS$1m

US$391m

Sep 25 2021n/an/a

US$397m

Jun 26 2021n/an/a

US$396m

Mar 27 2021n/an/a

US$375m

Dec 26 2020US$13mUS$1m

US$364m

Sep 26 2020n/an/a

US$301m

Jun 27 2020n/an/a

US$271m

Mar 28 2020n/an/a

US$248m

Dec 28 2019US$18mUS$1m

US$252m

Sep 28 2019n/an/a

US$231m

Jun 29 2019n/an/a

US$219m

Mar 30 2019n/an/a

US$227m

Dec 29 2018US$14mUS$1m

US$225m

Sep 29 2018n/an/a

US$135m

Jun 30 2018n/an/a

US$128m

Mar 31 2018n/an/a

US$129m

Dec 30 2017US$13mUS$1m

US$123m

Rémunération vs marché: La rémunération totale de Jim ($USD 14.10M ) est dans la moyenne des entreprises de taille similaire sur le marché US ($USD 12.66M ).

Rémunération et revenus: La rémunération de Jim a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.


PDG

Jim Foster (73 yo)

33.8yrs

Titularisation

US$14,096,923

Compensation

Mr. James C. Foster, J.D. has been the Chairman of the Board at Charles River Laboratories, Inc. (CRL) since 2000 and has been its Chief Executive Officer since 1992 and serves as its President since 1991....


Équipe de direction

NomPositionTitularisationCompensationPropriété
James Foster
CEO, President & Chairman33.8yrsUS$14.10m0.45%
$ 45.4m
Flavia Pease
Corporate Executive VP & CFO2.5yrsUS$3.81m0.0049%
$ 494.5k
Birgit Girshick
Corporate Executive VP & COO3yrsUS$4.99m0.083%
$ 8.3m
Joseph LaPlume
Corporate Executive Vice President of Corporate Development & Strategy13.8yrsUS$3.06m0.021%
$ 2.1m
William Barbo
Corporate Executive Vice President of Community Relations8.1yrsUS$2.91m0.050%
$ 5.1m
Michael Knell
Corporate Senior VP & Chief Accounting Officer7.6yrspas de données0.010%
$ 1.0m
Julie Frearson
Corporate Senior VP & Chief Scientific Officer3yrspas de donnéespas de données
Mark Mintz
Corporate Senior VP & Chief Information Officer3.4yrspas de donnéespas de données
Todd Spencer
Corporate Vice President of Investor Relationsno datapas de donnéespas de données
Matthew Daniel
Corporate Senior VP4.2yrspas de donnéespas de données
Amy Cianciaruso
Corporate Vice President & Chief Communications Officerno datapas de donnéespas de données
Victoria Creamer
Corporate Executive VP & Chief People Officer5.8yrspas de données0.020%
$ 2.0m

5.0yrs

Durée moyenne de l'emploi

54yo

Âge moyen

Gestion expérimentée: L'équipe dirigeante de CRL est chevronnée et expérimentée (5 années d'ancienneté moyenne).


Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
James Foster
CEO, President & Chairman35.8yrsUS$14.10m0.45%
$ 45.4m
Richard Wallman
Independent Director13.8yrsUS$339.77k0.022%
$ 2.2m
George Massaro
Lead Independent Director21.8yrsUS$371.02k0.010%
$ 1.0m
Virginia Wilson
Independent Director5.1yrsUS$346.02k0.0067%
$ 666.7k
Robert Bertolini
Independent Director13.8yrsUS$346.02k0.062%
$ 6.2m
Craig Thompson
Independent Director1.9yrsUS$437.78k0.0018%
$ 178.2k
Martin MacKay
Director7.3yrsUS$336.02k0.023%
$ 2.3m
Deborah Kochevar
Independent Director16.1yrsUS$339.77k0.014%
$ 1.4m
Nancy Andrews
Independent Director4.8yrsUS$339.77k0.0048%
$ 481.5k
George Llado
Independent Director4.1yrsUS$324.77k0.0049%
$ 486.5k
Reshema Kemps-Polanco
Independent Directorless than a yearpas de données0.00033%
$ 33.0k

7.3yrs

Durée moyenne de l'emploi

68yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de CRL sont considérés comme expérimentés (ancienneté moyenne 7.3 ans).